Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory
pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death …

The incidence of hepatocellular carcinoma (HCC) is increasing in industrialized societies;
this is likely secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD) …

Liver disease is the spectrum of liver damage ranging from simple steatosis called as
nonalcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). Clinically …

Deletions on chromosome 8p are common in human tumors, suggesting that one or more
tumor suppressor genes reside in this region. Deleted in Liver Cancer 1 (DLC1) encodes a …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide
and is highly correlated with hepatitis virus infection. Our previous report shows that a DEAD …

Enhancer of zeste homolog 2 (EZH2), an oncogene, is a commonly up‐regulated epigenetic
factor in human cancer. Hepatocellular carcinoma deletion gene 1 (DLC1) is an …

Abstract Fibrinogen-like protein 1 (FGL1) is a novel hepatokine that forms part of the
fibrinogen superfamily. It is predominantly expressed in the liver under normal physiological …

Despite liver cancer being the second-leading cause of cancer-related death worldwide, few
systemic drugs have been approved. Sorafenib, the first FDA-approved systemic drug for …

Background Human hepassocin (HPS) was originally detected by subtractive and
differential cDNA cloning as a liver-specific gene that was markedly upregulated during liver …

The protective role of fibrinogen‑like‑protein 1 (FGL1) in liver injury has been reported
previously. However, there are few studies on FGL1 expression in gastric cancer (GC) …